Cargando…
Reactogenicity to COVID-19 vaccination in the United States of America
PURPOSE: In the United States, Pfizer-BioNTech, Moderna, and Janssen’s coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze...
Autores principales: | Sanyaolu, Adekunle, Marinkovic, Aleksandra, Prakash, Stephanie, Desai, Priyank, Haider, Nafees, Abbasi, Abu Fahad, Mehraban, Nasima, Jain, Isha, Ekeh, Amarachi, Shazley, Omar, Okorie, Chuku, Orish, Verner N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844673/ https://www.ncbi.nlm.nih.gov/pubmed/35223671 http://dx.doi.org/10.7774/cevr.2022.11.1.104 |
Ejemplares similares
-
Navigating the Diagnostics of COVID-19
por: Sanyaolu, Adekunle, et al.
Publicado: (2020) -
Comorbidity and its Impact on Patients with COVID-19
por: Sanyaolu, Adekunle, et al.
Publicado: (2020) -
Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review
por: Sanyaolu, Adekunle, et al.
Publicado: (2022) -
The emerging SARS-CoV-2 variants of concern
por: Sanyaolu, Adekunle, et al.
Publicado: (2021) -
Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)